The research is on the use of cannabinoids for treating multiple sclerosis and other auto-immune diseases. This article reports the MCL funding and gives a surprisingly specific description of Prof. Meiri’s strategy. Unique Cannabinoid Profile May Help Control Autoimmune Dysfunction in Multiple Sclerosis
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint